Zepbound, whose active ingredient is tirzepatide, started life as a weight-management medication, and that is still how most people know it. Then came a second chapter. In December 2024 the FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity, and it was the first prescription medicine approved for that use. For a condition that had spent decades being treated entirely with devices, surgery and lifestyle change, that was genuinely new territory.
New territory invites noise. Approvals get retold as miracles or dismissed as marketing, and the person holding a Zepbound pen while wearing a CPAP mask at night is left sorting headlines from substance. This article does the narrower, more useful job: explaining what the approval actually covers, what it sits alongside, and what it does not say.
What was approved, in plain terms
An approval like this one means a regulator reviewed the evidence and concluded the medication can be prescribed for a specific use in a specific population. Here that use is moderate-to-severe obstructive sleep apnea, the population is adults with obesity, and the medication is Zepbound. It also means prescribers now have an approved medication option to consider as part of care for that condition, where before they had none.
It is worth being precise about what an approval is not. It is not a guarantee of any particular result for any particular person. It is not a statement that the medication is right for everyone in the population it names; that judgment is made one patient at a time, by a clinician, with that patient's history in front of them. And it is not a claim about other GLP-1 medications, whose approvals are their own. The December 2024 decision belongs to Zepbound specifically.
Approvals also come with the ordinary apparatus of prescription medicine: a prescriber decides to start it, chooses the dose path, and monitors how it goes, exactly as with any other prescription. Nothing about the sleep apnea indication turns Zepbound into something you evaluate for yourself. It widens the menu a clinician can choose from, and the choosing still happens the way choosing always happens.
One more piece of the approval language matters and is easy to miss: Zepbound is approved for this use as an addition to a reduced-calorie diet and increased physical activity. We will come back to that, because it shapes how the medication is meant to fit into care.
An addition, not a stand-alone
The diet-and-activity phrasing is not boilerplate. It positions the medication alongside the foundations rather than in place of them: a reduced-calorie diet, increased physical activity, and Zepbound added to that combination. Anyone who has spent time around weight-management treatment will recognize the shape, because it is the same architecture used across the category. The medication is one component of a plan, and the plan has other components that do real work.
For people taking Zepbound for sleep apnea, this framing has practical consequences. It means questions like what to eat and how to move are part of the treatment conversation rather than a side note to it. It also means the weekly injection is not the whole story to bring to appointments; the eating and activity parts of the plan belong in the same conversation, and so does everything else being done for the sleep apnea itself, which is where this article goes next.
Part of sleep apnea care, not a replacement for it
Obstructive sleep apnea has an established toolkit: positive airway pressure therapy, commonly called PAP, oral appliances, and in some cases surgery. Professional guidance positions Zepbound as part of sleep apnea care alongside therapies such as these, not as a substitute for them. The word alongside is the load-bearing one. Nothing in the approval recasts the medication as a replacement for a machine, an appliance or a procedure a clinician has prescribed.
So this deserves its own paragraph in bold terms: never reduce or stop PAP, an oral appliance or any other sleep apnea treatment on the basis of this article, of starting Zepbound, or of how well you feel you are doing. Changes to sleep apnea treatment belong with the clinician managing that treatment. Sleep apnea decisions and medication decisions may involve the same person, but they are separate decisions, and both deserve the professional context they require. If you are wondering how the pieces fit together in your case, that question is the appointment agenda, not a puzzle to solve alone.
It also helps to remember that sleep and body weight are connected in general terms, which is part of why this class of medications crossed into sleep medicine at all. We looked at that relationship from the other direction in Sleep and GLP-1 Weight Loss: The Overlooked Variable, which is about sleep's role in the weight side of the picture rather than about the approval.
GLP 1 Tracker AppZepbound's full titration ladder, weight over time and side effects with severity, kept privately on your phone for every appointment.
Get the app
What does not change about your week
One practical point gets lost in the novelty: for the person using it, Zepbound for sleep apnea still looks like Zepbound. It is the same weekly injection on the same titration ladder, begun at the starting dose and stepped up on the prescriber's schedule, with the same attention to how each step is tolerated. The side effects people watch for around dose increases are the same ones discussed for the weight management indication, and the habit of noting them with severity rather than just ticking a box serves the same purpose here.
The appointment agenda is where the difference shows up. Alongside the usual questions about tolerance and weight trend, there is now a second clinician's perspective in play, the one managing the sleep apnea, and the two conversations inform each other. A record you can show both of them, what you took, when, how you felt, what your weight is doing, is worth more in that setting than any amount of recall. It does not need to be elaborate; it needs to exist.
Why we will not tell you whether you qualify
The approval names moderate-to-severe obstructive sleep apnea and adults with obesity, and the natural next question is: does that include me? We are not going to answer it, and not only because we cannot. Determining severity takes a sleep evaluation. Determining whether a medication fits a particular person takes their history, their other conditions, their other medications and a clinician's judgment. It is not a lookup you can do from a paragraph.
You will notice this article cites no thresholds, no indexes and no ranges for either part of the approved population. That is deliberate. Numbers pulled out of context become self-assessment tools, and self-assessment is exactly the step that goes wrong: people who might benefit rule themselves out, and people who should not self-select rule themselves in. The productive version of this question is asked in an exam room, with your symptoms, your sleep history and your full situation on the table. Everything an article can usefully do happens before that: helping you walk in informed.
What tracking can and cannot do here
A word about our own corner of this, because it would be easy to overpromise. GLP 1 Tracker App does not track sleep. It has no sleep features of any kind, and we are not going to hint otherwise in an article about sleep apnea. Sleep evaluation is a clinical process, and the tools for it belong to clinicians.
What the app does cover is the Zepbound side of the picture, which is more of the picture than it sounds like. The dose log carries the real Zepbound titration ladder, so what you took and when is one tap each week and visible at appointments. Weight readings accumulate into the trend that prescribers ask about. The side effect diary records severity, which matters early in treatment and around dose steps. We laid out the full case in Zepbound Tracker: Shots, Weight and the Long Game. None of it diagnoses or treats anything, including sleep apnea; all of it makes the conversations with the clinicians who do those things more concrete.
That division of labor is the honest summary of this whole topic. The approval widened what is possible in sleep apnea care; clinicians decide who it fits; the machines and appliances it sits alongside stay unless the managing clinician says otherwise; and a private, careful record of your own treatment is what you can usefully hold onto through all of it.
Track the treatment you can seeDoses, weight and side effects in one private log. No account, no ads, nothing collected.
Download
Frequently asked questions
Is Zepbound approved for sleep apnea?
Yes. In December 2024 the FDA approved Zepbound, whose active ingredient is tirzepatide, for moderate-to-severe obstructive sleep apnea in adults with obesity. It was the first prescription medicine approved for that use. The approval covers its use as an addition to a reduced-calorie diet and increased physical activity.
Can Zepbound replace a CPAP machine?
No, and nothing in the approval or in professional guidance suggests treating it that way. Zepbound is positioned as part of sleep apnea care alongside therapies such as positive airway pressure, an oral appliance or surgery, not as a replacement for any of them. Never reduce or stop PAP or any other sleep apnea treatment on your own; changes to that treatment belong with the clinician managing it.
Do I qualify for Zepbound for sleep apnea?
That is a clinician's call, not something an article can or should answer. The approval is for moderate-to-severe obstructive sleep apnea in adults with obesity, and deciding whether a specific person fits that picture takes a proper evaluation. We deliberately cite no thresholds or ranges here. Bring your symptoms, your sleep history and your questions to a clinician who can assess you directly.
Can GLP 1 Tracker App help with my sleep apnea treatment?
Not with sleep itself. The app does not track sleep, and we would rather say that plainly than imply otherwise. What it does do is support the Zepbound side of the picture: a dose log on the real titration ladder, weight readings over time, and a side effect diary with severity, all of which can make conversations with your prescriber more concrete.
Why does the sleep apnea approval mention diet and exercise?
Because Zepbound is approved for sleep apnea as an addition to a reduced-calorie diet and increased physical activity, not as a stand-alone treatment. That framing is standard for weight-management medications and it carries real meaning: the medication is positioned to work alongside those foundations rather than in place of them. Your clinician can translate what that combination should look like in your case.